The transcription factor human X-box binding protein 1 (hXBP-1) is a basic region-leucine zipper protein implicated in the regulation of major histocompatibility complex class II gene expression as well as in exocrine gland and skeletal development. Multiple regulatory elements in the hXBP-1 promoter lie 3' to the transcription start site, including the hX2 site, whose core sequence is an AP-l-like element identical to the hXBP-1 target sequence in the HLA-DRA promoter. One complex identified by electrophoretic mobility shift assay (EMSA), complex 3, was previously shown to protect the hX2 site and more 3' bases. Sequence analysis now shows that this region contains a consensus binding site for transcription factor BSAP (B cell lineage-specific activator protein). Complex 3 and BSAP have identical cell-type specificities, as they are found only in pre-B and mature B cell lines. In EMSAs, BSAP antibody specifically recognized complex 3, and in vitro translated BSAP could bind to an hXBP promoter fragment. Cotransfections using an hXBP-1 reporter construct indicated that BSAP downregulates the hXBP-1 promoter. The highest levels of hXBP-1 mlKNA were found when BSAP was not expressed, in pre-pro-B cells and in plasma cell lines. In addition, hXBP-1 and BSAP levels were inversely correlated along the early stages of B cell development. In the regulation of the hXBP-1 promoter, a strong positive transcriptional influence at the hX2 site is opposed by the downregulatory actions of BSAP.
H
uman X-box binding protein 1 (hXBP-1) 1 is a transcription factor originally cloned because of its ability to bind an AP-l-like site, the X2 box in the promoter region of the MHC class II DRA and DPB genes (1) . hXBP-1 is a b-zip protein, containing a basic region that mediates DNA binding and an adjacent leucine zipper that mediates protein dimerization, for example with the oncoprotein Fos (2) . Examination of panels of tissues and cell lines has shown that hXBP-1 is expressed nearly ubiquitously in the adult. However, in situ hybridization studies in the developing embryo, probing for the murine homolog ofhXBP-1, revealed selective expression in chondroblasts and osteo~Abbreviations used in this paper: BSAP, B cell lineage~pecific activator protein; EMSA, electrophoretic mobility shift assay; hXBP-1, human X-box binding protein 1; R.T, reverse transcription; USF, upstream stimulatory factor. blasts in developing bone, of acinar cells in exocrine glands, and in adipose tissue (3) . To date, the only known function of hXBP-1 has been demonstrated by transfection of antisense hXBP-1 into the mature B cell line 1Kaji, causing decreased expression of the HLA DRA and DPB genes (2) . In addition, the strong localization to fetal cartilage, bone, and exocrine tissue has suggested that hXBP-1 may have an important role in exocrine gland and skeletal development.
The promoter of the hXBP-1 gene was recently isolated and a deletional and mutational analysis demonstrated that all functional promoter elements lie within positions -104 to + 128, in an area containing the conserved sequence elements CCAAT (-10 to -6), hX2 (+15 to +21), CCAAT/Y box (+31 to +40), and Sp-1 (+66 to +71, +81 to +86, and +88 to +93) (4) . An unusual feature is that five of these six elements are located downstream of the transcription start site. The hX2 site has a core recognition sequence identical to that of the class II D R A X2 box and is partially protected by two complexes that form on electrophoretic m obility shift assays (EMSAs) using probes o f the proximal promoter. Mutation of the hX2 site caused a 90% reduction in transcriptional activity o f an hXBP-1 promoter construct, establishing this site as an important regulatory region for hXBP-1 (4) .
It is now shown that the hXBP-1 proximal promoter is a target for a tissue-specific and developmentally regulated D N A binding activity, complex 3, which has a distribution identical to that o f the transcription factor BSAP (B cell lineage-specific activator protein) (5, 6) . In EMSAs, BSAP binding sites compete for complex 3, BSAP antibody specifically recognizes complex 3, and in vitro translated BSAP binds to an hXBP-1 promoter fragment. Cotransfection experiments demonstrate that overexpression of BSAP resuits in downregulation of the hXBP-1 promoter by acting at the hX2 site and more 3' sequences. In the B cell lineage, hXBP-1 mP,.NA levels are at their highest when BSAP levels are low or absent, at the pre-Pro-B cell and plasma cell stages. Thus, both positive and negative transcriptional regulators employ the same D N A sequence element in the hXBP-1 promoter, the hX2 site.
Materials and Methods
Cell Lines. All cell lines were grown in RPMI medium supplemented with 8% FCS, 100 Izg/ml penicillin and streptomycin, and 10 -4 M 2-ME.
Plasmids. The plasmid hX2-104/+128-CAT, containing hXBP-1 promoter sequences from -104 to +128 in the vector pSVOCAT, and the plasmid LS-hXBP-CAT, containing a 13-bp subsitution mutation centered at the hX2 site in the context of hX2-104/+ 128-CAT, have been described (4) . The hXBP-1 mutated CAT construct was identical to hX2-104/+ 128-CAT except for substitution of 5'-CATTCTAGATACTTACTTTAGG-3' at positions 15 to 36 of the hXBP-1 promoter. The vector pcl3Amp (a gift of M. Whatelet, Harvard University) was made from pcDNA-1/Amp (Invitrogen, San Diego, CA) by replacing the SV40 intron with a 13 globin intron. The expression plasmids for BSAP consisted of sequences 1 to 1409 of the BSAP cDNA (5) cloned in either sense or antisense orientations into the EcoRI and NotI sites of pc[3Amp or pSG5 (Stratagene Inc., La Jolla, CA). A frameshift mutation of hXBP-1, named delta hXBP-1, was created by digestion of the hXBP-1 cDNA with AvaI and BssHII to remove a 23-bp fragment in the 5' untranslated region, followed by Klenow treatment, religation, and cloning into the SalI and EcoRl site ofpcDNA-1 (Invitrogen). Proper orientation was confirmed by sequencing using the dideoxy chain termination method.
In Vitro Transcn)~tion and Translation. The cDNAs for hXBP (positions 13 to 795) and BSAP (positions l to 1409; a gift Dr. Meinrad Busslinger, Research Institute of Molecular Pathology, Vienna, Austria) were cloned into the polylinker of pBSKSII (Stratagene Inc.). Plasmid I2.2, containing the upstream stimulating factor (USF) cDNA in pBSKS was the gift of Dr. Robert P, oeder (The Rockefeller University, New York) and plasmid pT713k-3 containing the TFE3 cDNA in the pT713-globin vector was a gift of Dr. Tom Kadesch (University of Pennsylvania, Philadelphia, PA). In vitro transcription and translation were carfled out using MEGAscript TM and mMESSAGE mMACHINE TM kits (Ambion, Austin, TX) according to the manufacturer's recommendations, using [35S]rnethionine for radioactive labeling of protein.
EMSAs. Nuclear extracts from Raft and M12.4.1 cells were isolated as described (7) and were the gift of Dr. Terri Laufer (Harvard Medical School, Boston, MA). EMSAs using nuclear extracts were performed as described (4) . When using in vitro translated protein, the reaction mixture contained 1-3 ILl protein, 2 ~g poly d(I)d(C), 30,000 counts of 3ep-labeled probe, and 1 txl of 10X buffer (750 mM KCI, 100 mM Tris-HC1, pH 7.8, 10 mM dithiothreitol). This was incubated at room temperature for 20 rain, electrophoresed on a 4% acrylamide gel at 4~ followed by autoradiography using two sheets of x-ray film separated by a sheet of paper. Double-stranded oligonucleotide probes included hX2-BSAP, an hXBP-1 promoter fragment spanning positions +6 to +38 and comprising the hX2 site and the entire putative BSAP binding site extending into the CCAAT/Y box; hX2, identical to hX2-BSAP except for the deletion of 6 bp at the 3' end, removing part of the putative BSAP binding site (5'-GCT-CGGCCGTGCGTCACGCGACGCTGG-3'); hX2s, deleting a further 9 bp from the 3' end of the hX2 probe (5'-GCTCGGC-CGTGCGTCACG-3'); and histone sequences H2B-2.2 and H2A-2.1 (6) . The rout 1 competitor was derived from the hX2 sequence, with the substitution of the DQI3 AP-l-like site for the hXBP-1 AP-l-like site: 5'-GCTCGGCCGTGAGGTCCGC-GACGTGG-3' (substitution underlined). Antibody to BSAP was a gift of Dr. Meinrad Busslinger.
Transfections. Cotransfections were carried out using 5 Ixg of the plasmid hX2-104/+ 128-CAT along with 1-8 ~g of the desired expression plasmid, with pBSKSII DNA added to keep a constant amount of DNA in all transfections. Raji and HeLa cells were transfected by electroporation and M12.4.1 cells by the DEAE-dextran method, as described (8) . All transfections were harvested after 48 h, the cells were ruptured by three freeze--thaw cycles, and deacetylase activity was inactivated by incubation at 60~ for 10 min. The protein concentration was determined by commercial assay (Bio-Rad Laboratories, Richmond, CA) and was found to give results equivalent to normalizing for growth hormone activity generated by cotransfected pCMV-GH (9) in pilot experiments. 40-100 txg of protein was incubated for 3 h or overnight with [14C]chloramphenicol and fractionated by thinlayer chromatography. The ratio of incorporated to total 14C counts was determined by scintillation counting.
Reverse Transcription (RT)-PCR. R T -P C R was performed using B lineage cells at varying stages of differentiation (fractions A-F) isolated from murine bone marrow, as described (10) . Briefly, bone marrow cells from 2-4-mo-old female BALB/ cAnN mice were stained by a combination of either fluorescein anti-CD43 (FL-S7), PE anti-BP1, biotin anti-heat-stable antigen (BI-30F1), and allophycocyanin anti-B22 (APC-6B2) for t}ac-tions A-C, or FL-S7, PE anti-lgD, biotin-anti-lgM, and APC-6B2 for fractions D-F. Texas red-avidin was used to reveal the biotin reagent. Cell fractions were sorted directly into a cell lysis buffer by using flow cytometry (FACStar Plus| Becton Dickinson hnmunocytometry Systems, San Jose, CA) for further B.NA preparation. PCR primers for the nmrine homolog of hXBP-1 were 5'-CAGAGTAGCAGCGCAGACTGC-3' and 5'-GAG-GCAACAGTGTCAGAGTCC-3', spanned two intron-exon boundaries, and were predicted to give rise to a 352-bp band in the cDNA. Murine BSAP primers were 5'-TCCTCGGACCAT-CAGGACAG-3' and 5'-CCTGTTGATGGAGCTGACGC-3', spanned one intron-exon junction, and were predicted to pro-duce a 383-bp band. The sequences of the PCR products were confirmed by the dideoxy chain termination method.
Results

EMSA Complex 3 Shows Cell Type and Developmental
Specificity. To show that the entire hXBP-1 promoter had been isolated, transgenic mice were created using cosmid 20B, containing the hXBP-1 gene with 9 kb of 5' and 10.8 kb of 3' flanking sequence. Analysis of hXBP-1 m R N A levels indicated that the expression of the transgene paralleled the expression of the murine homolog of hXBP-1 in all tissues examined (data not shown), demonstrating that the transgene recreates the endogenous regulation ofhXBP-1.
Further analysis of the hXBP-1 promoter has focused on the hX2 site because of its functional importance in the expression of the hXBP-1 gene. EMSAs using hXBP-1 promoter sequences +9 to +104 gave rise to four complexes, of which only complex 3 could not be competed by M H C class II X and Y box sequences. In vitro footprinting by orthophenanthroline-copper demonstrated that complex 3 protected positions + 19 to +36 of the hXBP-1 5' untranslated region (4) . Examination of this sequence reveals it to be a consensus binding site for transcription factor BSAP, spanning parts of the hX2 site, the C C A A T / Y box, and the interspace between them (11, 12) (Fig. 1 ). The hXBP-1 promoter gives an even closer match to the BSAP consensus sequence than the sea urchin histone H2B-2.2 BSAP site ( Fig. 1 B) , a D N A sequence known to have a high affinity for BSAP (13) .
To determine if the expression of complex 3 is cell-type specific, nuclear extracts were used from a panel of cell lines. Fig. 2 A demonstrates that complex 3 appears only when R.aji B cell nuclear extract is used, and not when using M H C class II-negative T cell lines HPBALL and Jurkat, M H C class II-positive T cell line H U T 78, routine thymoma cell lines EL4 and BW5147, human myeloid leukemic cell line U937, colonic epithelial cell line C O L O 205, cervical epithelial cell line HeLa, or HeLa cells treated with IFN-~/to induce M H C class II expression. To further define at which stages of B cell development complex 3 is produced, nuclear extracts were made from a progenitor (Lyd-9), pre-B (70/Z, 230-238), mature B (M12.4.1., A20), and myeloma cell lines (XAg653, J558L). Fig. 2 B shows that complex 3 appears in pre-B and mature B cells (lanes 3-6) but is absent from the progenitor cell line and myeloma cells (lanes 2, 7, and 8). This same tissue distribution has been described for transcription factor BSAP (13) . When two strong BSAP binding sites, sea urchin histone sequences H2B-2.2 and H2A-2.1 (13), were used in EMSAs with nuclear extracts from our panel of B cell lines, the pattern of binding to the histone sequences was identical to the pattern of binding of complex 3 to the hXBP-1 promoter (Fig. 2, C and D) . As a control, no binding was seen using the hX2s probe, an 18-bp probe including the hX2 site of the hXBP-1 promoter, but missing the 3' half of the putative BSAP binding site (Fig. 2 E) .
The specificity of the protein-DNA interactions in complex 3 was confirmed by performing EMSAs using 1kaji nuclear extract with varying amounts of D N A competitors. Fig. 3 shows that the hXBP-1 promoter fragment hX2-BSAP, containing a complete potential BSAP binding site, competes as well for complex 3 as the known high-affinity BSAP binding site H2B-2.2. By contrast, the hX2 fragment, which contains a 6-bp truncation at its 3' end compared to hX2-BSAP, has an incomplete BSAP recognition sequence and competes only weakly, even at 100-fold excess. Three control fragments did not compete: the mutl fragment containing the DQ[3 AP-l-like site in the context of the hX2 probe, the transcription factor USF binding site, and the transcription factor TFE3 binding site p, E3 (not shown), even though USF and TFE3 binding sites showed sequence similarity to the hX2 site and more 3' sequences (4). These results provide strong evidence that BSAP or a closely related binding activity interacts with the 395 R.eimold et al. hXBP-1 promoter in a cell type-specific and developmentally regulated manner.
BSAP Antibody Recognizes Complex 3. Having obtained
evidence that the transcription factor BSAP is involved in the formation of complex 3, a polyclonal antibody to BSAP was then used to see if it would recognize specific complexes on EMSA with B cell nuclear extract. The antibody to BSAP supershifted complex 3 in EMSA using either the 95-bp SacI-BssHII (Fig. 4 A, lane 4) or the 27-bp hX2 probe from the hXBP-1 promoter (Fig. 4 B, lane 4) . Preimmune serum (Fig. 4, A and B, lane 3) had no effect. As a control, antibody to transcription factor TFE3 did not cause a change in the EMSA complexes (data not shown).
To demonstrate direct binding of BSAP to the hXBP-1 promoter, in vitro transcription and translation were performed using the c D N A of BSAP cloned into the vector pBS. After incubation of BSAP protein with the 95-bp hXBP-1 promoter fragment, electrophoresis showed binding of BSAP, which is known to bind as a monomer (Fig. 4  C) . R.eticulocyte lysate without added R N A , in vitro translated transcription factors USF, TFE3, and hYd3P-1, and mixtures of USF and h X B P -I or TFE3 and hXBP-1, showed no D N A binding activity (Fig. 4 C, and data (Fig. 5 A) . However, mutations in the putative BSAP binding site within h X 2 -1 0 4 / + 1 2 8 -C A T did affect C A T activity. A 13-bp mutation centered on the hX2 site, called LS-hXBP-CAT, allowed downregnlation by cotransfected BSAP of only 22%, whereas a more drastic mutation of the entire putative BSAP binding site, hXBP-1 mutated, essentially abolished the effect ofcotransfected BSAP (Fig. 5 B) . These experiments demonstrate that BSAP can downregulate the hXBP-1 promoter and that a BSAP binding site in the region from +15 to +37 mediates this effect.
BSAP and hXBP-1 Levels Vary Inversely in Early B Cell
Development. The powerful downregulatory effect of BSAP on the hXBP-1 promoter predicts that hXBP-1 levels might be high in cells with low or absent BSAP expression. BSAP and hXBP-1 levels were assessed in a panel of immortalized B cell lines representing various stages of maturation, including four plasma cell lines (Fig. 6 A) . As expected, BSAP m R N A was present only in pre-B and mature B cell lines, but absent from the progenitor cell hne Lyd-9 and from plasma cell lines (Fig. 6 A, top) . mR.NA for hXBP-1 was present in all cell lines examined and was most abundant in two plasma cell lines, H O P C IF/12 and J558L ( Fig. 6 A, 
middle).
Since the cell lines in Fig. 6 A are transformed, are of diverse origins, and have not been assigned a precise developmental maturity, R T -P C I ( was performed on nontransformed bone marrow-derived B cells (10) to assess BSAP and hXBP-1 levels. As shown in Fig. 6 , B and C, BSAP levels are near zero in pre-Pro-B cells (fraction A, before D-J rearrangement), increase as the B cells progress through the early Pro-B (fraction B, D-J rearranged) and late Pro-B (fraction C) stages, and peak at the pre-B stage (fraction D, Figure 3 . EMSA of the hXBP-1 promoter using competitor DNA. EMSA was carried out using the 95-bp hXBP-1 promoter fragment as probe, with Raji nuclear extract. Competitors were the BSAP binding site from the histone gene H2B-2.2, the 33-bp hX2-BSAP fragment (from +6 to +38 in the b_XBP-1 promoter), the 27-bp hX2 sequence (from +6 to +32 in the hXBP-1 promoter), mutl (containing a substitution of the DQ[~ X2 site in place of the 7-bp hX2 site), and a 30-bp fragment containing a USF binding site.
V-D-J rearranged). In the immature (fraction E) and mature B cell stages (fraction F), BSAP expression decreases. O n the other hand, hXBP-1 levels are highest in the prePro-B stage (fraction A) and decrease thereafter. There is an inverse relationship between BSAP and hXBP-1 expression in early B cell development, as seen in fractions A -D . Although hXBP-1 expression is not regulated by BSAP alone, hXBP-1 levels appear to be highest when BSAP expression is absent, such as in pre-Pro-B cells and in plasma cell lines.
Discussion
The transcription factor hXBP-1 was originally cloned from a )tgtll library by probing with a cychc A M P response element site from the murine M H C -A o t gene, The murine homolog of hXBP-1 is expressed ubiquitously in adult mice, with the highest levels of mP, NA found in lung, liver, spleen, and testis (3; R.eimold, A. M., and L. H. Glimcher, unpublished observations). During murine fetal development, hXBP-1 mP, NA reaches high levels in chondroblasts and osteoblasts, in exocrine glands such as the pancreas and salivary glands, in brown fat, and in whisker follicles (3) . In developing bone, the rise and fall of hXBP-1 m_RNA levels parallels that of alkaline phosphatase and tissue inhibitor ofmetalloproteinase, suggesting that common factors or stimuli regulate the transcription or mRNA stability of these three genes. Nevertheless, the role of hXBP-1 in developing fetal tissues has not been fully elucidated.
In studying the hXBP-1 promoter, a previous report described the presence of several conserved sequence elements in the 5' untranslated region of the gene (4). The hX2 site had a core sequence identical in seven of seven base pairs to the X2 site of the DRA promoter. In addition, a CCAAT/Y box was located 15 bp 3' of the hX2 site, producing a grouping in the hXBP-1 promoter similar to the canonical X and Y boxes of MHC class II promoters. EMSA of the proximal hXBP-1 promoter using Raji B cell nuclear extracts revealed four complexes, of which only complex 3 could not be competed for by MHC class II X or Y box sequences. Copper footprinting had shown that complex 3 spanned a 17-bp region extending 3' from the center of the hX2 site (4), an area that overlaps all but two bases of the 19-bp consensus BSAP site. It has now been established that complex 3 contains the transcription factor BSAP. The first piece of evidence for this was the tissue distribution of complex 3, which was found only in pre-B and mature B cell lines, but not in progenitor or plasma cell lines (Fig. 4) , using the high-affinity histone H2A-2.1 and H2B-2.2 BSAP binding site probes (13) as comparisons to an hXBP-1 promoter probe in EMSA. This distribution of expression for complex 3 is identical to that described for BSAP (13) . The presence of complex 3 was not correlated with expression of MHC class II molecules, since complex 3 was absent in the class II-positive T cell line HUT 78 and in HeLa cells induced to express class II by treatment with IFN-y. The specificity of complex 3 for a DNA probe containing a potential BSAP binding site was demonstrated by EMSA using competitor DNA or mutated BSAP sites. Probes with intact BSAP sites (histones H2B-2.2 and H2A.2.1, and hX2-BSAP from the hXBP-1 promoter) competed for complex 3, whereas probes without intact BSAP sites (hX2, hX2s, hX2 mutl, bLE3 site, USF site) competed weakly or not at all. Direct evidence that BSAP or an antigenically related protein forms complex 3 was provided by use ofpolyclonal antiserum to BSAP. BSAP antibody specifically shifted complex 3 in EMSA, whether using the 95-bp or 27-bp hX2 probe from the hXBP-1 promoter. In addition, in vitro translated BSAP protein bound to the 95-bp probe, whereas other in vitro translated transcription factors hXBP-1, USF, and TFE3 showed no binding, even when given the opportunity to form homodimers or heterodimers. A probe from the hXBP-1 promoter containing the hX2 site and sequences 3' to it had been used to screen a Xgtl 1 expression library and resulted in the isolation of a clone for TFE3 (Ponath, P. D., J. L. Strominger, and L. H. Glimcher, unpublished observations). Potential binding sites for TFE3 and USF can indeed be identified within and 3' to the hX2 site in the hXBP-1 promoter. O u r inability to demonstrate binding of in vitro translated TFE3, USF, or hXBP-1 proteins to this region may indicate a requirement for different binding conditions that we were unable to achieve, or the presence of potential binding sites that are not occupied by these factors under more physiologic conditions.
Targeted disruption o f BSAP in the mouse germline has demonstrated postnatal growth retardation, abnormal morphogenesis of the midbrain and cerebellum, and arrest of B cell differentiation at an early precursor stage in BSAP-deficient mice (14) . From this phenotype, it appears likely that BSAP regulates genes important for the growth o f the skeletal system, of which hXBP-1 is one candidate. Most known BSAP binding sites are located upstream of genes specific to the B cell lineage, such as CD19, VpreB and ~5, and the S region of immunoglobulin genes (15) (16) (17) (18) (19) . Although the hXBP-1 gene has now also been shown to contain a BSAP binding site, hXBP-1 has no known role in the processes of B cell differentiation, switch recombination, or immunoglobulin gene expression.
By downregulating the hXBP-1 gene, BSAP may indirectly influence M H C class II levels in B ceils. BSAP m R N A levels peak at the pre-B cell stage and remain substantial in mature B cells (Fig. 6) , preceding the expression of M H C class II, which is at very low levels in pre-B cell lines and peaks in mature B cell lines (20) . However, the promoters of the M H C class II genes do not contain highaffinity BSAP binding sites (13) , suggesting that BSAP does not directly influence class II transcription. Nevertheless, antisense hXBP-1 can downmodulate the levels of M H C class II DRcx and DP[3 expression in the mature B ceil line Raft (2), and BSAP might have a similar effect by decreasing hXBP-1 levels, indirectly reducing class II levels. Such a mechanism provides only a partial explanation o f M H C class II regulation, since neither BSAP nor hXBP-1 levels show a strict correlation with class II expression.
There is a striking inverse relationship of hXBP-1 and BSAP mRNA levels in the earliest stages of B cell development, with the pre-Pro-B stage (fraction A in Fig. 6 C) showing very low BSAP and high hXBP-1 levels, followed by a steady rise in BSAP but a concomitant drop in hXBP-1 levels thereafter, through the pre-B cell stage (fraction D). These findings suggest that BSAP is a powerful downregulator of the hXBP-1 gene in the B cell lineage, since in those circumstances where BSAP is absent (pre-Pro-B and plasma cell stages), hXBP-1 levels are at their highest. However, there are likely to be other important regulators of hXBP-1 mRNA levels, since BSAP and hXBP-1 levels do not vary inversely in all cases (e.g., Fig. 6 C, fractions E and F). A further downregulator ofhX13P-1 expression has been identified as hXBP-1 itself, which in cotransfection experiments represses its own promoter by ~40%, acting at the hX2 site (our unpublished observations). Elimination of hXBP-1 expression by targeted disruption of its gene is expected to provide more definitive information on the role ofhXBP-1 in B cell development.
BSAP acts as a positive or negative regulator of gene transcription, depending on its target of action. In this study, BSAP negatively regulated the activity of an hXBP-1 promoter fragment from sequences -104 to + 128. In addition, BSAP was recently shown to repress the mouse immunoglobulin heavy chain 3'oL enhancer, allowing increased activity of the enhancer in terminally differentiated plasma cells, where BSAP is absent (21, 22) . On the other hand, BSAP is required for induction by lipopolysaccharide and IL-4 of~ germline transcripts (23) , and the BSAP sites from 5' of Sy2a and from the CD19 promoter function as positive promoter elements in vitro (15, 16) . Multiple other BSAP binding sites, within and 5' of immunoglobulin switch regions, in blk, and in VpreB and k5 genes, have not yet been shown to have positive or negative regulatory activity (24) .
Individual DNA sequence elements have been shown to mediate either positive or negative transcriptional regulation, depending on the combination of bound transcription factors and their levels (25) . For example, the composite glucocorticoid response element, plfG, showed enhanced transcription when bound by glucocorticoid receptor plus c-Jun homodimers, but transcription was repressed upon binding of glucocorticoid receptor plus c-Jun/c-Fos heterodimers (26) . Similarly, one can postulate that hXBP-1, BSAP, and an unknown positively acting transcription factor combine in various ratios at the hX2 site, which might behave as a composite response element. In this model, hXBP-1 binds at the hX2 site, BSAP binds at hX2 and to more 3' sequences, and the putative positive factor makes further protein-protein or protein-DNA contacts to ensure a positive transcriptional response. However, when BSAP or hXBP-1 are overexpressed in transfection experiments, they may alter the balance of transcription factors or displace the positively acting factor, resulting in repression of transcription. In this model, although a transcription factor such as hXBP-1 is ubiquitously expressed, it may achieve cell-type specificity by interacting with a unique combination of DNA sequences and transcription factors (25) .
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